220 related articles for article (PubMed ID: 15837335)
1. Design and synthesis of potent pyridazine inhibitors of p38 MAP kinase.
Tamayo N; Liao L; Goldberg M; Powers D; Tudor YY; Yu V; Wong LM; Henkle B; Middleton S; Syed R; Harvey T; Jang G; Hungate R; Dominguez C
Bioorg Med Chem Lett; 2005 May; 15(9):2409-13. PubMed ID: 15837335
[TBL] [Abstract][Full Text] [Related]
2. p38 MAP kinase inhibitors. Part 6: 2-arylpyridazin-3-ones as templates for inhibitor design.
Natarajan SR; Heller ST; Nam K; Singh SB; Scapin G; Patel S; Thompson JE; Fitzgerald CE; O'Keefe SJ
Bioorg Med Chem Lett; 2006 Nov; 16(22):5809-13. PubMed ID: 16945533
[TBL] [Abstract][Full Text] [Related]
3. Discovery and design of benzimidazolone based inhibitors of p38 MAP kinase.
Hammach A; Barbosa A; Gaenzler FC; Fadra T; Goldberg D; Hao MH; Kroe RR; Liu P; Qian KC; Ralph M; Sarko C; Soleymanzadeh F; Moss N
Bioorg Med Chem Lett; 2006 Dec; 16(24):6316-20. PubMed ID: 17010605
[TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.
Liverton NJ; Butcher JW; Claiborne CF; Claremon DA; Libby BE; Nguyen KT; Pitzenberger SM; Selnick HG; Smith GR; Tebben A; Vacca JP; Varga SL; Agarwal L; Dancheck K; Forsyth AJ; Fletcher DS; Frantz B; Hanlon WA; Harper CF; Hofsess SJ; Kostura M; Lin J; Luell S; O'Neill EA; O'Keefe SJ
J Med Chem; 1999 Jun; 42(12):2180-90. PubMed ID: 10377223
[TBL] [Abstract][Full Text] [Related]
5. Discovery of pyridazinopyridinones as potent and selective p38 mitogen-activated protein kinase inhibitors.
Wu B; Wang HL; Pettus L; Wurz RP; Doherty EM; Henkle B; McBride HJ; Saris CJ; Wong LM; Plant MH; Sherman L; Lee MR; Hsieh F; Tasker AS
J Med Chem; 2010 Sep; 53(17):6398-411. PubMed ID: 20712346
[TBL] [Abstract][Full Text] [Related]
6. Novel p38 inhibitors with potent oral efficacy in several models of rheumatoid arthritis.
Revesz L; Blum E; Di Padova FE; Buhl T; Feifel R; Gram H; Hiestand P; Manning U; Rucklin G
Bioorg Med Chem Lett; 2004 Jul; 14(13):3595-9. PubMed ID: 15177482
[TBL] [Abstract][Full Text] [Related]
7. The development of new bicyclic pyrazole-based cytokine synthesis inhibitors.
Townes JA; Golebiowski A; Clark MP; Laufersweiler MJ; Brugel TA; Sabat M; Bookland RG; Laughlin SK; VanRens JC; De B; Hsieh LC; Xu SC; Janusz MJ; Walter RL
Bioorg Med Chem Lett; 2004 Oct; 14(19):4945-8. PubMed ID: 15341957
[TBL] [Abstract][Full Text] [Related]
8. Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.
Colletti SL; Frie JL; Dixon EC; Singh SB; Choi BK; Scapin G; Fitzgerald CE; Kumar S; Nichols EA; O'Keefe SJ; O'Neill EA; Porter G; Samuel K; Schmatz DM; Schwartz CD; Shoop WL; Thompson CM; Thompson JE; Wang R; Woods A; Zaller DM; Doherty JB
J Med Chem; 2003 Jan; 46(3):349-52. PubMed ID: 12540232
[TBL] [Abstract][Full Text] [Related]
9. Inhibitors of unactivated p38 MAP kinase.
Bullington J; Argentieri D; Averill K; Carter D; Cavender D; Fahmy B; Fan X; Hall D; Heintzelman G; Jackson P; Leung WP; Li X; Ling P; Olini G; Razler T; Reuman M; Rupert K; Russell R; Siekierka J; Wadsworth S; Wolff R; Xiang B; Zhang YM
Bioorg Med Chem Lett; 2006 Dec; 16(23):6102-6. PubMed ID: 16971122
[TBL] [Abstract][Full Text] [Related]
10. Discovery and characterization of triaminotriazine aniline amides as highly selective p38 kinase inhibitors.
Lin TH; Metzger A; Diller DJ; Desai M; Henderson I; Ahmed G; Kimble EF; Quadros E; Webb ML
J Pharmacol Exp Ther; 2006 Aug; 318(2):495-502. PubMed ID: 16702443
[TBL] [Abstract][Full Text] [Related]
11. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
[TBL] [Abstract][Full Text] [Related]
12. The design and synthesis of novel alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Ernst JT; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Mar; 18(6):1772-7. PubMed ID: 18325768
[TBL] [Abstract][Full Text] [Related]
13. Structure-based design, synthesis, and biological evaluation of imidazo[1,2-b]pyridazine-based p38 MAP kinase inhibitors.
Kaieda A; Takahashi M; Takai T; Goto M; Miyazaki T; Hori Y; Unno S; Kawamoto T; Tanaka T; Itono S; Takagi T; Hamada T; Shirasaki M; Okada K; Snell G; Bragstad K; Sang BC; Uchikawa O; Miwatashi S
Bioorg Med Chem; 2018 Feb; 26(3):647-660. PubMed ID: 29291937
[TBL] [Abstract][Full Text] [Related]
14. The development of monocyclic pyrazolone based cytokine synthesis inhibitors.
Golebiowski A; Townes JA; Laufersweiler MJ; Brugel TA; Clark MP; Clark CM; Djung JF; Laughlin SK; Sabat MP; Bookland RG; VanRens JC; De B; Hsieh LC; Janusz MJ; Walter RL; Webster ME; Mekel MJ
Bioorg Med Chem Lett; 2005 May; 15(9):2285-9. PubMed ID: 15837310
[TBL] [Abstract][Full Text] [Related]
15. 'Reverse' alpha-ketoamide-based p38 MAP kinase inhibitors.
Montalban AG; Boman E; Chang CD; Ceide SC; Dahl R; Dalesandro D; Delaet NG; Erb E; Gibbs A; Kahl J; Kessler L; Lundström J; Miller S; Nakanishi H; Roberts E; Saiah E; Sullivan R; Wang Z; Larson CJ
Bioorg Med Chem Lett; 2008 Oct; 18(20):5456-9. PubMed ID: 18835164
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
17. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
18. Synthesis, crystal structure, and activity of pyrazole-based inhibitors of p38 kinase.
Graneto MJ; Kurumbail RG; Vazquez ML; Shieh HS; Pawlitz JL; Williams JM; Stallings WC; Geng L; Naraian AS; Koszyk FJ; Stealey MA; Xu XD; Weier RM; Hanson GJ; Mourey RJ; Compton RP; Mnich SJ; Anderson GD; Monahan JB; Devraj R
J Med Chem; 2007 Nov; 50(23):5712-9. PubMed ID: 17948975
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of novel disubstituted dibenzosuberones as highly potent and selective inhibitors of p38 mitogen activated protein kinase.
Koeberle SC; Fischer S; Schollmeyer D; Schattel V; Grütter C; Rauh D; Laufer SA
J Med Chem; 2012 Jun; 55(12):5868-77. PubMed ID: 22676210
[TBL] [Abstract][Full Text] [Related]
20. Discovery and optimization of p38 inhibitors via computer-assisted drug design.
Goldberg DR; Hao MH; Qian KC; Swinamer AD; Gao DA; Xiong Z; Sarko C; Berry A; Lord J; Magolda RL; Fadra T; Kroe RR; Kukulka A; Madwed JB; Martin L; Pargellis C; Skow D; Song JJ; Tan Z; Torcellini CA; Zimmitti CS; Yee NK; Moss N
J Med Chem; 2007 Aug; 50(17):4016-26. PubMed ID: 17658737
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
